Clinical & Translational

The partners will use Cypher's software to diagnose rare diseases in the Clinic's unique patient population, which includes Amish and Mennonite patients.

NanoString will develop a companion diagnostic for Merck's anti-PD-1 immunotherapy based on immune-related gene expression signatures.

Under the partnership, the companies will help drugmakers efficiently implement complementary and companion tests through lab networks.

The firm will discontinue its SensiGene Fetal RHD test.

The firm is aiming at in vitro diagnostics, applied markets, and next-generation sequencing sample preparation.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.